FCMI
CRNX icon

Foresite Capital Management IV’s Crinetics Pharmaceuticals CRNX Stock Holding History

Foresite Capital Management IV’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-49,600
Closed -$1.42M – 19
2018
Q3 		$1.42M Buy
+49,600
New +$1.47M 0.47% 19

Other funds holding CRNX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foresite Capital Management IV's CRNX Position: Q4 2018 in Review

Foresite Capital Management IV sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2018, closing a stake of 49,600 shares — an estimated $1.42M sold.

Foresite Capital Management IV first reported a position in CRNX in Q3 2018 and held it in 1 quarter. The position peaked at $1.42M in Q3 2018. 50 funds tracked by Wall St. Rank hold CRNX as of Q4 2018.

  • Foresite Capital Management IV reported no remaining Crinetics Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Foresite Capital Management IV sold 49,600 Crinetics Pharmaceuticals shares in Q4 2018, an estimated $1.42M.
  • Foresite Capital Management IV first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Foresite Capital Management IV's Crinetics Pharmaceuticals position peaked at $1.42M in Q3 2018.
  • 50 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2018.

Based on Foresite Capital Management IV's 13F filing for Q4 2018, filed 13 Feb 2019.